Massimo Cristofanilli
Impact in
- Cancer Research top 0.01%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Oncology top 0.01%
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 368
- Cancer Cells and Metastasis 164
- HER2/EGFR in Cancer Research 91
- Cancer Treatment and Pharmacology 61
- Cancer Immunotherapy and Biomarkers 33
- Cancer Research 248
- Cancer Genomics and Diagnostics 146
- Breast Cancer Treatment Studies 95
- Co-authors
- Gabriel N. Hortobágyi (96 shared papers)James M. Reuben (68 shared papers)Daniel F. Hayes (12 shared papers)Michael Craig Miller (12 shared papers)Gerald V. Doyle (11 shared papers)Leon W.M.M. Terstappen (9 shared papers)Jeri Matera (9 shared papers)G. Thomas Budd (7 shared papers)
- Journals
- Journal of Clinical Oncology (116 papers)Cancer Research (80 papers)Cancer (30 papers)Breast Cancer Research and Treatment (27 papers)Annals of Oncology (26 papers)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Massimo Cristofanilli
587 papers receiving 38.1k citations
Massimo Cristofanilli's Hit Papers
Peers
Comparison fields: 5 of 159
- Cancer Research 14.7k
- Oncology 21.0k
- Pulmonary and Respiratory Medicine 9.6k
- Genetics 1.3k
- Pathology and Forensic Medicine 2.0k
Countries citing papers authored by Massimo Cristofanilli
This map shows the geographic impact of Massimo Cristofanilli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Cristofanilli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Cristofanilli more than expected).
Fields of papers citing papers by Massimo Cristofanilli
This network shows the impact of papers produced by Massimo Cristofanilli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Cristofanilli. The network helps show where Massimo Cristofanilli may publish in the future.
Co-authors
The 25 scholars most cited alongside Massimo Cristofanilli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 604 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer Hit paper breakdown → | 2004 | 3583 |
| 2 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Hit paper breakdown → | 2008 | 2214 |
| 3 | Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Hit paper breakdown → | 2005 | 1423 |
| 4 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2016 | 1278 |
| 5 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2015 | 1140 |
| 6 | Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System Hit paper breakdown → | 2007 | 1109 |
| 7 | Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer Hit paper breakdown → | 2005 | 871 |
| 8 | Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer Hit paper breakdown → | 2005 | 860 |
| 9 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2018 | 813 |
| 10 | Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival Hit paper breakdown → | 2006 | 808 |
| 11 | Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer Hit paper breakdown → | 2006 | 596 |
| 12 | Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer Hit paper breakdown → | 2016 | 515 |
| 13 | 2006 | 475 | |
| 14 | 2002 | 461 | |
| 15 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial Hit paper breakdown → | 2018 | 415 |
| 16 | 2011 | 358 | |
| 17 | 2010 | 334 | |
| 18 | The Landscape of Targeted Therapies in TNBC Hit paper breakdown → | 2020 | 327 |
| 19 | 2005 | 326 | |
| 20 | 2004 | 310 |
About Massimo Cristofanilli
Massimo Cristofanilli is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 604 papers that have together received 38.8k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (164 papers), Cancer Genomics and Diagnostics (146 papers), Advanced Breast Cancer Therapies (121 papers), Breast Cancer Treatment Studies (95 papers), HER2/EGFR in Cancer Research (91 papers), Cancer Treatment and Pharmacology (61 papers), Cancer Immunotherapy and Biomarkers (33 papers) and Genetic factors in colorectal cancer (27 papers). The work is most often cited by research in Cancer Research (14.7k citations), Oncology (21.0k citations), Pulmonary and Respiratory Medicine (9.6k citations), Genetics (1.3k citations) and Pathology and Forensic Medicine (2.0k citations). Massimo Cristofanilli has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Gabriel N. Hortobágyi, James M. Reuben, Daniel F. Hayes, Michael Craig Miller, Gerald V. Doyle, Leon W.M.M. Terstappen, Jeri Matera, G. Thomas Budd, W. Jeffrey Allard and Lajos Pusztai. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Cancer, Breast Cancer Research and Treatment and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.